Drug Trial Radar · NCT07000136
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
473
Actual
Start
Jun 10, 2025
Primary completion
Jan 4, 2027
Study completion Jan 4, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to evaluate the efficacy and safety of AZD0780 in adults with HeFH and elevated LDL-C, either with clinical ASCVD and LDL-C levels of 55 mg/dL or higher or without clinical ASCVD and LDL-C levels of 70 mg/dL or higher. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study. The total length of the study for an individual participant will be up to approximately 56 weeks, including a screening period of up to 14 days, treatment with AZD0780 or placebo for 52 weeks, and a safety follow-up period of 10 days.
Conditions
- Heterozygous Familial Hypercholesterolaemia
Interventions
AZD0780Drug
Participants will receive daily oral dose of AZD0780
PlaceboDrug
Participants will receive daily oral dose of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative change in LDL-C from baseline to 12 weeksTime frame: Baseline - 12 weeks
Locations
133 sites in 24 countries. Site status is shown where the registry gives one.
Research Site
Garden Grove, California
Research Site
San Diego, California
Research Site
Miami Lakes, Florida
Research Site
Orlando, Florida
Research Site
Peachtree Corners, Georgia
Research Site
Chicago, Illinois
Research Site
Hammond, Louisiana
Research Site
Las Vegas, Nevada
Research Site
New York, New York
Research Site
Morganton, North Carolina
Research Site
Cincinnati, Ohio
Research Site
Lima, Ohio
Research Site
Chattanooga, Tennessee
Research Site
Houston, Texas
Research Site
Humble, Texas
Research Site
Kingwood, Texas
Research Site
McAllen, Texas
Research Site
Mesquite, Texas
Research Site
Redmond, Washington
Research Site
CABA, Argentina
Research Site
Ciudad Autonoma de Bs As, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Mar del Plata, Argentina
Research Site
Rosario, Argentina
Research Site
Rosario, Argentina
Research Site
Melbourne, Australia
Research Site
Campinas, Brazil
Research Site
São Caetano do Sul, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
Plovdiv, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Vancouver, British Columbia, Canada
Research Site
London, Ontario, Canada
Research Site
Chicoutimi, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Showing 40 of 133 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.